A securities class action has been filed against Caribou Biosciences, Inc. (CRBU) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Caribou common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about July 23, 2021 (the “IPO” or “Offering”); and/or (b) Caribou securities between July 23, 2021 through December 9, 2022.  This case has been filed in the USDC – N.D.CA.

On or around July 26, 2021, Caribou conducted its initial public offering (“IPO”), selling 19 million shares of stock priced at $16.00 per share.

Then, on December 12, 2022, Caribou issued a press release “report[ing] new 12-month clinical data from cohort 1 in the ongoing ANTLER Phase 1 trial, which show long-term durability following a single infusion of CB-010 at the initial dose level 1 (40×106 CAR-T cells).” Among other results, Caribou reported that “3 of 6 patients maintained a durable CR [complete response] at 6 months” and “2 of 6 patients maintain a long-term CR at the 12 month scan and remain on the trial”.

On this news, Caribou’s stock price fell $0.81 per share, or 9.03%, to close at $8.16 per share on December 12, 2022.